Please login to the form below

Not currently logged in
Email:
Password:

Bayer finances sustainable development chair at Chinese university

Bayer says it will finance a chair in sustainable development at Tongji University in China

German-based pharmaceutical company Bayer has said it will finance a chair in sustainable development at Tongji University in China.

The chair is a joint project with Tongji University and the UN Environment Programme (UNEP). Bayer will support the new chair, student scholarships and research activities for an initial period of five years with a sponsorship of USD 1m.

The Bayer-Tongji Chair for Sustainable Development will focus on advanced education and research into emerging environmental technologies. It will also support sustainable development projects which enhance China's solutions to environmental, economic and social sustainability problems.

Member of Bayer's management board, Wolfgang Plischke, said: "The path China takes to achieve sustainable growth and protect its environment will have far-reaching effects. We know the government is committed to meeting the challenges, and Bayer is here to help."

Zhao Jianfu, vice-president of Tongji University, added: "The University considers environmental protection and sustainable development one of its top priorities. We are delighted to be working closely with Bayer, a company known worldwide for its outstanding achievements in the area of sustainability."

China plans to reduce its energy consumption and emissions by 20 and 10 per cent, respectively, between 2006 and 2010. To achieve this, the country says it needs help for funding and technologies.

Bayer already provided new technologies and specialised services for China in wastewater treatment, environmental protection and conversion of biological energy sources, added Plischke.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics